ASH 2014: Highlights in multiple myeloma
ASH 2014: Highlights in multiple myeloma
Tyrosine kinase inhibitor in combination with chemo shows benefit in acute myeloid leukaemia
Paediatric leukaemia treatment regimens lead to improved outcomes in adolescents and young adults
Targeted therapy effective in elderly patients with Philadelphia-positive acute lymphocytic leukaemia
First randomised evidence for benefit from adding a tyrosine kinase inhibitor in acute myeloid leukaemia
Chemo-free treatment approach demonstrates positive responses in leukaemia patients
Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma
Nivolumab shows early promise in Hodgkin lymphoma
Blinatumomab demonstrates significant clinical activity in residual ALL
New immunotherapy compound effective, safe in ALL patients with minimal residual disease
T cell therapy leading to prolonged remission for children with aggressive leukaemia
Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma